Soleno Therapeutics Inc
F:6XC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Soleno Therapeutics Inc
F:6XC
|
US |
|
Unicaja Banco SA
MAD:UNI
|
ES |
|
Compass Pathways PLC
NASDAQ:CMPS
|
UK |
|
B
|
BP PLC
F:BPE5
|
UK |
|
A
|
Archer-Daniels-Midland Co
DUS:ADM
|
US |
|
Vitura Health Ltd
ASX:VIT
|
AU |
|
V
|
Vodafone Group PLC
F:VODI
|
UK |
|
C
|
Cintas Corp
SWB:CIT
|
US |
|
A
|
Apple Inc
F:APC
|
US |
|
Becle SAB de CV
BMV:CUERVO
|
MX |
|
FINEOS Corporation Holdings PLC
ASX:FCL
|
IE |
|
Gartner Inc
NYSE:IT
|
US |
|
Central Pacific Financial Corp
NYSE:CPF
|
US |
|
G
|
Global Green Chemicals PCL
SET:GGC
|
TH |
|
T
|
Tanzanian Gold Corp
F:TRG
|
CA |
|
Z
|
Zendesk Inc
F:0ZD
|
US |
|
Klepierre SA
OTC:KLPEF
|
FR |
Wall St Price Targets
6XC Price Targets Summary
Soleno Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for 6XC is 59.78 EUR with a low forecast of 55.62 EUR and a high forecast of 87.29 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 6XC's stock price target?
Price Target
59.78
EUR
According to Wall Street analysts, the average 1-year price target for 6XC is 59.78 EUR with a low forecast of 55.62 EUR and a high forecast of 87.29 EUR.
What is the Revenue forecast for Soleno Therapeutics Inc?
Projected CAGR
75%
Over the last 12 years, the compound annual growth rate for Revenue has been 41%. The projected CAGR for the next 3 years is 75%.
What is the Operating Income forecast for Soleno Therapeutics Inc?
Projected CAGR
307%
The compound annual growth rate for Operating Income over the next 3 years is 307%.
What is the Net Income forecast for Soleno Therapeutics Inc?
Projected CAGR
188%
The compound annual growth rate for Net Income over the next 3 years is 188%.
